18 results about "Lipid peroxide" patented technology

The invention provides application of a small molecule drug for promoting triple negative breast cancer ferroptosis, and belongs to the technical field of tumor treatment. The inducer can effectively kill triple negative breast cancer cells by triggering a ferroptosis pathway. The invention discovers that the inhibitor can reduce the expression of a key protein RPTOR by inhibiting the activity of an mTORCl compound, thereby weakening the anti-oxidation defense capability of triple negative breast cancer cells, greatly enhancing the accumulation of lipid peroxide, and further strongly inducing the occurrence of ferroptosis. The component of the culture medium is a DMEM (Dulbecco Modified Eagle Medium) containing 10% of fetal calf serum, and 2 [mu] M of Torinl is added at the same time. The invention discloses a new target spot of ferroptosis of the triple-negative breast cancer, and provides a new thought for treatment of the triple-negative breast cancer.

The invention relates to the field of biological medicine, in particular to a nanoparticle for treating myocardial ischemia reperfusion injury, a preparation method and application. According to the scheme, the nanoparticles comprise liposome containing ML351, a phase change material PFP is sealed in the liposome, and a TA-Ce metal polyphenol network coating is wrapped outside the liposome. The TA-Ce coating ensures that the system actively anchors myocardial cells through multiple acting forces, continuously removes ROS, and creates a primary protection environment for the myocardial cells. Under ultrasonic triggering, the PFP in the inner core is subjected to phase change blasting, local enrichment and accurate release of ML351 are realized, lipid peroxide is reduced, a ferroptosis pathway is blocked, and sequential treatment under space-time control is realized. A network structure of TA-Ce removes ROS, and TA-Ce and ML351 inhibit lipid peroxidation, and upstream and downstream synergy is formed on an anti-oxidation and anti-ferroptosis pathway, so that the overall treatment effect is greatly enhanced.

The application relates to a composition for treating reflux esophagitis and application thereof. The composition comprises the following components in parts by weight: 2-8 parts of scutellaria baicalensis, 3-7 parts of licorice, 5-10 parts of beeswax and 80-120 parts of vegetable oil. The composition for treating reflux esophagitis contains scutellaria baicalensis, licorice, beeswax and vegetable oil, and through mutual cooperation among the components, the drug prepared from the composition can significantly increase the plasma motilin level of a patient, further increase the pressure of the lower esophageal sphincter, promote gastric emptying and prevent acid reflux, promote the recovery of reflux esophagitis, the esophagus of the patient is obviously improved, and no adverse reaction is found; meanwhile, the content of lipid peroxide can be obviously reduced, the activities of superoxide dismutase and glutathione peroxidase are increased, the esophageal mucosa is protected and treated, the pathological changes of the esophagus are obviously improved, and the treatment effect is excellent.

The invention relates to A61K35, in particular to hair growth essence and application of the hair growth essence in scalp aging protection. The hair growth essence is prepared from the following raw materials in parts by weight: 20 to 45 parts of active ingredients, 5.2 to 7.5 parts of glycerol, 0.015 to 0.025 part of auxiliary active ingredients, 0.6 to 0.9 part of stabilizer and 50 to 74 parts of deionized water. The hair-growing essence provided by the invention has excellent free radical scavenging activity and lipid peroxide inhibition activity, and is beneficial to prevention of alopecia caused by oxidative stress, promotion of hair growth, prevention of white hair and inhibition of scalp aging.

The invention belongs to the technical field of microbial fermentation, and discloses a solid-state fermentation postbiotic for adjusting the 5-hydroxytryptamine level and a preparation method and application of the solid-state fermentation postbiotic, and the solid-state fermentation postbiotic comprises fermented fermentation lactobacillus mucus IOB802 inactivated thallus components, metabolites and fermentation substrate active components. According to the invention, after solid state fermentation, by adjusting the content of neurotransmitters such as 5-hydroxytryptamine and then adjusting the relative expression level of neuronal cell apoptosis related genes Bcl-2 and Caspase 3 mRNA, nerve injury caused by sleep disorder is further improved. Meanwhile, after solid state fermentation, the prebiotics can improve oxidative stress injury caused by sleep disorder by reducing the content of lipid peroxide malonaldehyde and increasing the content of antioxidant enzyme.

The application discloses a selenium-based metal polyphenol-based nanoparticle and a preparation method and application thereof, and belongs to the technical field of biological materials. The selenium-based metal polyphenol-based nanoparticle is composed of a selenium-based catalytic center, metal ions and non-enzyme molecular ligands, and a stable nano structure is constructed through coordination of the metal ions and polyphenols. The application also discloses a preparation method of the nano enzyme. The nano enzyme can efficiently remove lipid peroxides and lipid hydroperoxides under the participation of glutathione, and has very low non-specific catalytic activity to the POD pathway. The nanoparticle has good biocompatibility, can effectively reduce lipid peroxidation damage induced by oxidative stress, and can maintain the stability of the structure and function of the cell membrane, and can be used for prevention and treatment of oxidative stress-related diseases, and is especially suitable for diseases with lipid peroxidation and ferroptosis as the main pathological mechanism.

The application discloses a 4-(benzo[d]thiazol-2-yl)benzene-1,2-ethylenediamine compound and a preparation method and application thereof. The structural formula of the compound is: the compound has strong ROS scavenging capacity, inhibits lipid peroxidation, can inhibit ferroptosis caused by an iron death inducer, can reduce brain ischemia and nerve damage caused by brain ischemia, and can relieve symptoms of Parkinson's syndrome and other neurological diseases. Therefore, the ferroptosis inhibitor based on the ferrostain-1 / lirilad structure provided by the application can treat diseases related to ferroptosis through multiple actions and has the potential to be developed into a drug for treating diseases related to ferroptosis. Moreover, the ferroptosis inhibitor can be used as an antioxidant fluorescent probe for high-sensitivity detection of a ferroptosis marker, lipid peroxide (PCOOH / PEOOH), can effectively reverse the ferroptosis process of cells, and has a self-indication capacity. The ferroptosis inhibitor is a solid powder, is convenient to store and use, has a simple synthesis method, high yield, low cost, and good popularization prospect.

The invention discloses application of NAC in preparation of a medicine for treating temporomandibular joint disorder, and particularly discloses application of the medicine in effectively improving TMD joint tissue oxidation resistance, inhibiting inflammation level, promoting extracellular matrix secretion and inhibiting iron (ferrous) ions and lipid peroxides so as to improve cartilage injury, relieve pain in a condylar process region and improve osteoarthritis. As a clinical common medicine, NAC is low in cost, high in availability, excellent in cell and tissue safety and high in practicability. The medicine can be safely applied to TMD treatment by means of condyle local injection or condyle region skin application (microneedle) and the like, has important significance in clinical medication of TMD, and has good medication value and application prospect.

The invention discloses a preparation method of astaxanthin immobilized probiotic vesicles capable of resisting ionizing radiation liver injury, and belongs to the field of biological medicines. Preparing probiotic vesicles by taking lactobacillus rhamnosus as a raw material; the preparation method comprises the following steps: dissolving astaxanthin in absolute ethyl alcohol, dispersing vesicles in a phosphate buffer solution, mixing the two vesicles in a microreactor, and carrying out ultrasonic treatment to obtain astaxanthin-loaded probiotic vesicles; the immobilized probiotic vesicles loaded with the astaxanthin are obtained by incubating the immobilized probiotic vesicles with glutamine transaminase, so that the embedding rate and the loading rate of the astaxanthin are improved, and the immobilized probiotic vesicles have good biocompatibility and biological safety; the residence time of fat-soluble compounds in intestinal tracts is prolonged, and targeted enrichment of the liver is increased; x-ray induced active oxygen accumulation, mitochondrial dysfunction and DNA damage in cells are relieved, the antioxidant enzyme level is improved, and the lipid peroxide content is reduced; the liver injury caused by ionizing radiation is remarkably relieved by reducing oxidative stress and DNA injury of the liver and delaying cell apoptosis.

The invention discloses an anti-aging beautifying oral liquid containing low-polymerization-degree chitosan oligosaccharide and a preparation method thereof, and belongs to the technical field of marine organisms. Chitosan oligosaccharide mainly comprising chitobiose and chitotriose is prepared by utilizing the synergistic fermentation effect of microorganisms, and the chitosan oligosaccharide is compounded with collagen, sodium hyaluronate, vitamin C and the like to prepare the oral liquid. The low-polymerization-degree chitosan oligosaccharide is an excellent in-vivo antioxidant, can remove excessive free radicals, inhibit lipid peroxidation and slow down damage of metabolites such as peroxided lipid to the body, and then the anti-aging effect is achieved; the anti-aging and beautifying oral liquid prepared by matching natural moisturizing and beautifying components such as collagen and sodium hyaluronate is good in taste and easy to absorb, and animal experiment results show that the anti-aging and beautifying oral liquid can have beautifying and anti-aging effects after being frequently taken.

The present application relates to the use of [10]-shogaol in the preparation of a medicament for preventing and / or treating tumors sensitive to ferroptosis. Specifically, the present application provides a method for screening ferroptosis inducers, comprising the following steps: taking cells sensitive to ferroptosis, applying a candidate compound to a test group, applying [10]-shogaol to a positive control group, applying [6]-shogaol to a non-ferroptosis inducer group, and not applying any compound to a blank control group; detecting the lipid peroxidation level in the cells of each group; comparing the lipid peroxidation levels of the test group and the other groups to detect whether the candidate compound is a ferroptosis inducer. The [10]-shogaol can effectively induce ferroptosis in various malignant tumor cells such as breast cancer, colorectal cancer, melanoma, etc., and the mechanism of action depends on the accumulation of lipid peroxidation, and this effect can be specifically blocked by ferroptosis inhibitors.

An object of the present invention is to provide a low molecular weight compound having an anti-ferroptosis activity and an ability to scavenge lipid peroxy radicals which is relatively highly safe when ingested, can be orally ingested, and can be manufactured at a relatively low cost. The present invention provides a ferroptosis inhibitor, an agent for preventing or treating a disease associated with ferroptosis, a lipid peroxy radical scavenger, or an agent for preventing or treating a disease caused by lipid peroxide accumulation and / or lipid peroxy radicals, comprising one or more compounds selected from the group consisting of compounds of the following formula (I) to formula (III):(wherein R represents H; a substituted or unsubstituted, linear or branched C1-20 alkyl group; a substituted or unsubstituted, linear or branched C2-20 alkenyl group; or —(CH2CH═CH(CH3)CH2)nH [wherein n represents an integer of 1 to 12]) and physiologically acceptable salts thereof.

This invention discloses a novel application of undecanoic acid in inducing ferroptosis in laryngeal cancer cells and in the preparation of anti-laryngeal cancer drugs. For the first time, it was discovered that the known compound undecanoic acid can specifically target the mitochondria of laryngeal cancer cells, inducing mitochondrial structural damage and dysfunction. This, in turn, activates the ferroptosis pathway through multiple mechanisms, including increasing intracellular ferrous ion accumulation, increasing lipid peroxide levels, downregulating GPX4 / SLC7A11 expression, and upregulating ACSL4 expression, thereby effectively inhibiting the proliferation of laryngeal cancer cells. Based on this mechanism, this invention provides a pharmaceutical composition with undecanoic acid as the active ingredient, and its combined application with platinum-based drugs (such as cisplatin). This combined treatment exhibits a significant synergistic effect, particularly overcoming the platinum resistance of laryngeal cancer cells. This invention provides a novel drug selection and combination therapy strategy for the treatment and prevention of laryngeal cancer and precancerous lesions.

This invention belongs to the field of biomedical technology and provides an application of a ferroptosis inhibitor in the treatment of hepatitis. This invention reveals that a GRIM-19 gene defect specifically induces ferroptosis in hepatocytes, rather than other cell death mechanisms such as apoptosis, necrosis, or autophagy. This invention provides a ferroptosis inhibitor with Ferrostatin-1 as the active ingredient, solving the technical problem of insufficient intervention against the ferroptosis mechanism in existing hepatitis treatments. This inhibitor can significantly increase the expression level of GPX4 in liver tissue, effectively clear lipid peroxides, a core toxic product in the ferroptosis process, and block the ferroptosis process; in addition, it can significantly inhibit the activation of the NLRP3 inflammasome and reduce the expression of downstream inflammatory factors, thereby alleviating inflammatory cell infiltration and fibrotic lesions in the liver. This invention is applicable to the treatment of GRIM-19 deficiency-related chronic hepatitis, providing a new strategy for targeted therapy of liver diseases.

The invention relates to the technical field of biological medicine, in particular to a bioactive material for tumor treatment and a preparation method and application thereof. The preparation method comprises the following steps: providing adriamycin-loaded magnesium-iron layered double-metal hydroxide nanoparticles; modifying the nanoparticles with glucose oxidase to obtain a drug-loaded enzyme compound; and dispersing the drug-loaded enzyme compound in water, mixing with shewanella, and carrying out centrifugal washing to obtain the bioactive material. The bioactive material disclosed by the invention has tumor targeting property, and in-vivo targeting can better utilize the metabolic function of bacteria to continuously consume metabolites at tumor parts; the apoptosis of tumor cells can be promoted by utilizing the generation of active oxygen and the release of adriamycin hydrochloride, and the ferroptosis of tumors can be realized by reducing glutathione and accumulating lipid peroxide.

The invention relates to application of dihydromyricetin in preparation of a medicine for preventing or treating amyotrophic lateral sclerosis. Through specific natural active ingredient selection and pharmacological mechanism integration, dihydromyricetin is used as an active ingredient for preparing the ALS treatment medicine, and the nerve protection effect is achieved by directly utilizing the inherent pharmacological characteristics of dihydromyricetin; dihydromyricetin resists nerve injury induced by neurotoxin BMAA, acts on motor neuron denaturation in a targeting manner, remarkably improves axonal structure injury, effectively blocks oxidative stress mediated nerve injury chain reaction by reducing the content of lipid peroxide and improving the activity of antioxidant enzyme, and meanwhile, effectively inhibits oxidative stress mediated nerve injury chain reaction by reducing the content of lipid peroxide and improving the activity of antioxidant enzyme. By means of multi-dimensional regulation and control of a neurotransmitter system and ALS related genes, systematic neuroprotection from morphology and biochemical indexes to the molecular level is achieved.

The invention relates to the technical field of biological medicines, and discloses a GPX4 mimic phospholipid-like material, and a liposome and application thereof. The general structural formula of the GPX4 simulated phospholipid-like material is shown in the specification, wherein X is a phospholipid head group and is choline, ethanolamine, serine, glycerol or inositol; sn-1 and sn-2 positions are ester bonds or ether bonds, and are respectively covalently connected with R1 and R2 groups at the tail part; r1 and R2 are respectively one of an aliphatic chain, an organic selenium compound simulating GPX4 or a derivative thereof. The aliphatic chain is a saturated aliphatic chain or a monounsaturated aliphatic chain; the organic selenium compound for simulating the GPX4 function is ebbeselenene or a derivative thereof. The ferroptosis inhibition liposome prepared by adopting the GPX4 simulation type phospholipid-like material has the capabilities of removing lipid peroxide and inhibiting cell ferroptosis, has the characteristics of high stability and long cycle, and can be used for preparing medicines for relieving and / or treating dry age-related macular degeneration (AMD).

The invention provides application of ALKBH related genes in regulation and control of salt stress resistance of poplars, and relates to the technical field of plant genetic engineering. The invention discovers the salt stress resistance of the poplar gene PtoALKBH2 for the first time. A salt tolerance experiment result shows that compared with a non-transgenic poplar, the expression quantity of the PtoALKBH2 gene in the transgenic poplar is greatly improved, the accumulation of lipid peroxides and active oxygen of a transgenic plant under salt stress is remarkably reduced, the activity of antioxidant enzyme is remarkably enhanced, oxidative damage and cell death are reduced, and the PtoALKBH2 gene in the transgenic poplar is remarkably improved. The salt tolerance of the transgenic poplar is also enhanced. The overexpression of the PtoALKBH2 gene can be used for enhancing the salt tolerance of the poplar, so that the poplar can be conveniently used for breeding stress-resistant varieties in forestry, and the adverse effect of salt stress on production is relieved.